Last reviewed: June 23, 2026

Last updated: June 23, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic (semaglutide) revolutionized weight loss treatment by mimicking glucagon-like peptide-1, a hormone that controls hunger and blood sugar. However, brand-name medications carry high costs and supply constraints, prompting many patients to explore compounded alternatives and newer dual-action therapies that may deliver superior results for certain metabolic profiles.

Understanding GLP-1 Receptor Agonists Beyond Ozempic

GLP-1 receptor agonists work by activating receptors in the brain's appetite center, slowing stomach emptying, and improving insulin sensitivity. Ozempic was designed for diabetes but showed remarkable weight loss effects—patients lost an average of 15% of body weight in clinical trials. The mechanism is well-established, yet Ozempic's brand-name price tag and frequent shortages have made compounded semaglutide a practical solution for uninsured and under-insured patients seeking the same active ingredient.

PlexusDx's compounded semaglutide injection delivers identical pharmaceutical-grade semaglutide from licensed 503A compounding pharmacies, available to all 50 states without insurance requirements. The dose flexibility mirrors Ozempic's titration schedule, allowing your provider to adjust based on tolerance and results, while your monthly cost remains fixed—your dose may need to go up, but your price won't. This transparency removes the financial anxiety that often derails long-term adherence.

Tirzepatide: The Dual-Action Alternative That Often Outperforms Semaglutide

Tirzepatide activates both GLP-1 and GIP receptors, a dual-hormone approach that produces greater weight loss than semaglutide alone. Clinical trials published in 2023 showed tirzepatide participants lost up to 22% of body weight—significantly more than semaglutide's 15% average. This dual mechanism not only suppresses appetite more potently but also enhances metabolic rate and improves liver fat accumulation, benefits that extend beyond scale numbers.

PlexusDx offers compounded tirzepatide injection starting at $249 per month and oral tirzepatide at $279 per month, making this advanced therapy accessible without the premium pricing of brand-name Mounjaro or Zepbound. For patients who plateau on semaglutide or have insulin resistance and metabolic syndrome, tirzepatide often delivers breakthrough results. The flat monthly pricing model applies equally to tirzepatide, meaning you control the cost while your prescriber controls the dose.

GLP-Squared: Combining Semaglutide and Tirzepatide for Maximized Results

PlexusDx's proprietary GLP-Squared formulation blends compounded semaglutide and tirzepatide into a single injection, offering synergistic GLP-1 and GIP receptor activation without the complexity of managing two separate medications. This approach can accelerate weight loss, improve adherence by reducing injection frequency, and provide more nuanced metabolic tuning for patients with complex health profiles. The combination allows providers to dial in both compounds based on individual response, rather than being limited to fixed ratios.

GLP-Squared injection begins at $249 per month and oral GLP-Squared at $369 per month, delivering dual-compound benefits at a lower cost than purchasing semaglutide and tirzepatide separately. Early clinical practice data suggests GLP-Squared users experience faster initial weight loss and more stable appetite suppression compared to monotherapy, particularly in patients with leptin resistance or impaired GLP-1 receptor sensitivity—conditions identifiable through genetic testing.

Precision Peptide Genetic Testing: Personalize Your GLP-1 Choice

Not every patient responds equally to semaglutide, tirzepatide, or dual protocols—genetics play a measurable role. PlexusDx's Precision Peptide Genetic Test ($99 add-on after first month) analyzes 14 metabolic pathways and 150+ genetic insights, including critical variants like GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313. These markers predict your body's natural sensitivity to GLP-1 signaling, appetite regulation capacity, and fat-cell metabolism, allowing your provider to select the compound most likely to work for your unique biology.

Patients with specific GLP1R or GIPR variants often show enhanced response to tirzepatide over semaglutide monotherapy, while those with FTO or MC4R variants may benefit from higher-intensity protocols or combination approaches. By testing before committing to a single therapy, you avoid months of trial-and-error dosing and accelerate entry into your optimal weight loss protocol. The genetic data also informs dose adjustments and helps predict side-effect tolerance, making treatment planning evidence-based rather than guesswork.

Cost, Access, and Practical Advantages Over Brand-Name Alternatives

Ozempic's retail price exceeds $900 per month for uninsured patients, and Mounjaro and Zepbound similarly command premium pricing. PlexusDx's compounded semaglutide at $149 per month and tirzepatide at $249 per month represent 80% savings compared to brand alternatives, with zero insurance requirements and no membership fees. All medications are HSA/FSA-eligible, meaning you can use pre-tax healthcare savings to cover treatment—a financial advantage many patients overlook.

PlexusDx serves all 50 states with medications from licensed 503A compounding pharmacies, ensuring pharmaceutical-grade quality, sterility, and potency. Patients can start treatment within days of completing their health questionnaire, avoiding the insurance authorization delays that plague brand-name prescriptions. Whether you choose semaglutide, tirzepatide, GLP-Squared, or the microdose GLP-1 protocol ($129/mo for semaglutide-sensitized individuals), PlexusDx's flat-rate model removes price variability and makes sustainable weight loss financially predictable.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide as effective as Ozempic?

Yes. Compounded semaglutide from licensed 503A pharmacies contains the identical active pharmaceutical ingredient as Ozempic, manufactured to the same FDA standards for purity and potency. The only difference is cost and supply reliability—PlexusDx's compounded semaglutide starts at $149 per month versus Ozempic's $900+, with consistent availability across all 50 states.

Why does tirzepatide produce more weight loss than semaglutide?

Tirzepatide activates both GLP-1 and GIP receptors, while semaglutide activates GLP-1 only. The dual-hormone mechanism produces roughly 7% greater weight loss on average—22% body weight reduction for tirzepatide versus 15% for semaglutide—because GIP activation enhances insulin secretion and energy expenditure beyond what GLP-1 alone achieves.

What does the Precision Peptide Genetic Test tell me about my GLP-1 response?

The test analyzes 14 metabolic pathways and identifies genetic variants like GLP1R rs6923761 and GIPR rs1800437 that predict your natural sensitivity to GLP-1 and GIP signaling. Patients with specific variants often respond better to tirzepatide over semaglutide or benefit from combination therapy, helping your PlexusDx provider select your optimal compound before you begin treatment.

Are there side effects with compounded GLP-1 medications?

Compounded semaglutide and tirzepatide carry the same side-effect profile as brand alternatives: nausea, vomiting, constipation, and fatigue during dose escalation are common and typically resolve within 2–4 weeks. Serious complications like pancreatitis are rare but require medical supervision. PlexusDx providers monitor your response and adjust doses to minimize tolerability issues while maximizing weight loss.

Can I use HSA or FSA funds to pay for PlexusDx treatment?

Yes. All PlexusDx medications, including semaglutide, tirzepatide, GLP-Squared formulations, and the Precision Peptide Genetic Test, are HSA/FSA-eligible expenses. This allows you to pay with pre-tax healthcare savings, effectively reducing your out-of-pocket cost by 20–35% depending on your tax bracket.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves